Haloperidol treatment induces tissue- and sex-specific changes in DNA methylation: a control study using rats

Table 1 Body weight and plasma concentrations of prolactin and haloperidol for control and haloperidol-treated rats

Sex	Treatment^a	Body weight (g) at		Plasma concentrations of
		beginning	end	prolactin (ng/ml)	haloperidol (ng/ml)
Male	haloperidol	351.5 ± 6.9	476.0 ± 8.4	64.7 ± 43.7	4.3 ± 0.9^b
	placebo	342.5 ± 6.3	473.0 ± 9.5	37.3 ± 10.0^b	1.5, 2.0, <1.3^c
Female	haloperidol	211.0 ± 15.2	298.0 ± 16.9	441.1 ± 243.3	ND
	placebo	211.0 ± 12.9	300.0 ± 15.6	150.5 ± 112.7^b	ND

^aEach group consisted of 10 rats.
^bn = 5
^cHaloperidol was below the detection limit in three of the five rats examined.
ND: not determined due to a high background activity of unknown origin.
Plasma concentrations of prolactin and haloperidol were determined by the [¹²⁵I]-labelled radioimmunoassay and colloidal gold immunoassay, respectively.

ISSN: 1744-9081